Envisage report cover

Women’s Healthcare Market - By Type Of Drug (EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28)), By Application (Hormonal Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraceptives, Menopause, Pcos, And Other), And By Region (North America, Asia Pacific, Europe, Middle East & Africa and Latin America) - Industry Analysis, opportunity and Forecast 2020 To 2027

Published Date: May 2021

No. of Pages: 196

Status: Published

Report Code: ARI100721

The global women’s healthcare market is projected to reach USD 22.72 billion by 2027 from USD 11.24 billion in 2020, at a CAGR of 10.6% during the forecast period (2020-2027). Growing incidence of chronic as well as infectious disease among female population will drive the women health care market growth during the forecast period.

According to the American Institute for Cancer Research, breast cancer is the most commonly occurring cancer among women, accounting for over 2 million new cases in 2020. Additionally, in 2020, around 268,600 new cases of invasive breast cancer are estimated in the U.S. women. Growing adoption of unhealthy diet and lifestyle changes will increase the disease burden thereby, augmenting the women health devices industry growth. Moreover, increasing prevalence of infectious disease among females in the underdeveloped economies due to unhygienic environment will favour business growth. Furthermore, technological advancement coupled with increasing demand for minimally invasive procedures will render positive impact on the business growth. Numerous efforts undertaken by government and other organizations to raise awareness regarding women’s health, management to reduce disease burden and promote availability of advanced technologies for diseases diagnosis and treatment will further drive industry growth. For instance, the Office on Women's Health (OWH) addresses critical women's health issues by educating patients and healthcare professionals, advancing policies as well as supporting innovative programs. However, high cost of devices along with lack of awareness among women especially in underdeveloped economies may impede women health devices industry growth to certain extent over the forecast timeframe.

According to the International Osteoporosis Foundation (IOF), the global incidence of osteoporosis among females is expected to reach 680 million in 2050. Moreover, breast cancer, cardiovascular diseases, and mental diseases significantly contribute to the burden of non-communicable diseases. Women most likely start to undergo menopause after the age of 48 wherein they experience hormonal changes that affect the quality of life. About 73.0% of postmenopausal women experience hot flashes. The Society of Obstetricians and Gynaecologists of Canada (SOGC) estimated that 80.0% of women suffer from at least one symptom of menopause such as mood swings, interrupted sleep, and irritability.

The market is fragmented in nature, with a large number of players, including tier 1 and mid-tier companies competing for market shares. The prominent players in the global market include Bayer AG (Germany), Allergan (Dublin), Merck & Co. (US), Pfizer Inc. (US), Amgen (US), Agile Therapeutics Inc. (US), Ferring Pharmaceuticals (US), Mylan N.V. (US), Lupin (India), Blairex Laboratories (US), and Apothecus Pharmaceutical (US).

Amgen (US) is one of the leading providers of the women’s healthcare market. The company’s sales and marketing activities are greatly focused on the US and Europe. The company provides Prolia and Xgeva for the treatment of osteoporosis in postmenopausal women. These drugs have shown a year-on-year double-digit value gain as well as volume growth, and constitute the largest share of the market. Amgen’s EVENITY, meant for the treatment of osteoporosis in postmenopausal women, is also in phase 3 of development. It is being developed in collaboration with UCB (Belgium). The company’s high brand recognition and focus on product innovation have helped it to maintain its foothold in the market.

Analyst commentary

The growth of the market is primarily driven by factors such as the growing incidence of chronic health conditions among women, government initiatives to curb population growth, and growing demand for contraceptives to prevent unintended pregnancies. Moreover, the growing focus on R&D by key players for the development of advanced products is also a major factor in driving market growth.

In 2020, the postmenopausal osteoporosis segment accounted for the largest market share during the forecast period. Factors such as the growing prevalence of postmenopausal osteoporosis, the focus of pharmaceutical players on providing effective drugs for postmenopausal osteoporosis, and the high risk of osteoporosis fractures supported the growth of this segment. Additionally, factors such as old age and obesity further add to the risk of osteoporosis in women. This segment is also expected to register the highest CAGR during the forecast period.

Prolia is the fastest-growing segment of the market. Also, Prolia accounted for the larger share of the market in 2020. The increasing demand for Prolia due to the high prevalence of postmenopausal osteoporosis among women is the major factor responsible for the growth of this market segment.

Segmentation

The global women’s healthcare market is segmented based on type of drug, application, and region. Based on drug, the market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28). Based on application, the market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, PCOS, and other applications.

Regional Analysis

North America women health devices market held over 33% revenue share in 2020 owing to increasing awareness among women regarding their health and hygiene. Technological advancements in gynecological and orthopedic devices will surge its adoption in the region. Strong foothold of prominent industry players in the region, focusing on various strategies such as novel product launch will positively impact industry expansion.

Asia Pacific’s women health devices market will witness lucrative CAGR of more than 7% during the forecast timeframe. Large patient pool in highly populated countries such as China and India, prone to various infectious and chronic diseases will act as primary driver in the regional business growth. Furthermore, growing awareness and favourable government support pertaining to women health will augment regional industry growth during the forthcoming years.

TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data Component
2.3.1. Secondary Component
2.3.1.1. Preliminary data mining
2.3.2. Primary Component
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Women’s healthcare Market
Chapter 5. Global Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027(USD Million)
5.1. Global Women’s healthcare Market Share, By Type of Drug, 2015 - 2027 (USD Million)
5.1.1. EVISTA
5.1.1.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. XGEVA
5.1.2.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.3. Prolia
5.1.3.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.3.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.4. Zometa
5.1.4.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.4.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.5. Reclast
5.1.5.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.5.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.6. Minastrin
5.1.6.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.6.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.7. NuvaRing
5.1.7.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.7.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Global Women’s healthcare Market Overview, By application, 2015 - 2027(USD Million)
6.1. Global Women’s healthcare Market Share, By application, 2015 - 2027 (USD Million)
6.1.1. Hormonal infertility
6.1.1.1. Market Type and Projections,2015 - 2027 (USD Million)
6.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. Postmenopausal osteoporosis
6.1.2.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.3. Endometriosis
6.1.3.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.3.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.4. Contraceptives
6.1.4.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.4.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.5. Menopause
6.1.5.1. Market Type and Projections, 2015 - 2027 (USD Million)
Chapter 7. Global Women’s healthcare Market Overview, By Geography, 2015 - 2027(USD Million)
7.1. Global Women’s healthcare Market Share, By Geography, 2015 - 2027(USD Million)
7.1.1. Market Type and projections, by Countries, 2015 - 2027 (USD Million)
7.1.2. Market Share and CAGR Comparison, by Countries, 2020 - 2027 (%)
Chapter 8. North America Women’s healthcare Market Overview, By Countries, 2015 - 2027(USD Million)
8.1. North America Women’s healthcare Market Overview, 2015 - 2027 (USD Million)
8.1.1. Market Type and projections, 2015 - 2027 (USD Million)
8.1.2. North America Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
8.1.3. North America Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
8.1.4. North America Women’s healthcare Market Overview, By Countries, 2015 - 2027 (USD Million)
8.1.4.1. U.S. Women’s healthcare Market Overview, 2015 - 2027 (USD Million)
8.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Million)
8.1.4.1.2. U.S. Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
8.1.4.1.3. U.S. Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
8.1.4.2. Canada Women’s healthcare Market Overview, 2015 - 2027 (USD Million)
8.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Million)
8.1.4.2.2. Canada Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
8.1.4.2.3. Canada Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
8.1.4.3. Mexico Women’s healthcare Market Overview, 2015 - 2027 (USD Million)
8.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Million)
8.1.4.3.2. Mexico Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
8.1.4.3.3. Mexico Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
Chapter 9. Europe Women’s healthcare Market Overview, By Countries, 2015 - 2027(USD Million)
9.1. Europe Women’s healthcare Market Overview, 2015 - 2027 (USD Million)
9.1.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.2. Europe Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
9.1.3. Europe Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
9.1.4. Europe Skin Care Types Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1.4.1. Germany
9.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.1.2. Germany Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027(USD Million)
9.1.4.1.3. Germany Women’s healthcare Market Overview, By application, 2015 - 2027(USD Million)
9.1.4.2. France
9.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.2.2. France Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027(USD Million)
9.1.4.2.3. France Women’s healthcare Market Overview, By application, 2015 - 2027(USD Million)
9.1.4.3. UK
9.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.3.2. UK Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027(USD Million)
9.1.4.3.3. UK Women’s healthcare Market Overview, By application, 2015 - 2027(USD Million)
9.1.4.4. Italy
9.1.4.4.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.4.2. Italy Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027(USD Million)
9.1.4.4.3. Italy Women’s healthcare Market Overview, By application 2015 - 2027(USD Million)
9.1.4.5. Spain
9.1.4.5.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.5.2. Spain Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027(USD Million)
9.1.4.5.3. Spain Women’s healthcare Market Overview, By application, 2015 - 2027(USD Million)
9.1.4.6. Rest of Europe
9.1.4.6.1. Market Type and projections, 2015 – 2027
9.1.4.6.2. Rest of Europe Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027(USD Million)
9.1.4.6.3. Rest of Europe Women’s healthcare Market Overview, By application, 2015 - 2027(USD Million)
Chapter 10. Asia Pacific Women’s healthcare Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1. Asia Pacific Women’s healthcare Market Overview, 2015 - 2027 (USD Million)
10.1.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.2. Asia Pacific Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
10.1.3. Asia Pacific Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
10.1.4. Asia Pacific Women’s healthcare Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.4.1. India
10.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.4.1.2. India Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027(USD Million)
10.1.4.1.3. India Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
10.1.4.2. China
10.1.4.2.1. Market Type and projections, 2015 - 2027(USD Million)
10.1.4.2.2. China Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027(USD Million)
10.1.4.2.3. China Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
10.1.4.3. Japan
10.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.4.3.2. Japan Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027(USD Million)
10.1.4.3.3. Japan Women’s healthcare Market Overview, By application, 2015 - 2027(USD Million)
10.1.4.4. South Korea
10.1.4.4.1. Market Type and projections, 2015 - 2027(USD Million)
10.1.4.4.2. South Korea Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027(USD Million)
10.1.4.4.3. South Korea Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
10.1.4.5. Rest of Asia Pacific
10.1.4.5.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.4.5.2. Rest of Asia Pacific Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027(USD Million)
10.1.4.5.3. Rest of Asia Pacific Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
Chapter 11. Middle East & Africa Women’s healthcare Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Middle East & Africa Women’s healthcare Market Overview, 2015 - 2027 (USD Million)
11.1.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.2. Middle East & Africa Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
11.1.3. Middle East & Africa Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
11.1.4. Middle East & Africa Women’s healthcare Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.4.1. GCC
11.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.4.1.2. GCC Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
11.1.4.1.3. GCC Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
11.1.4.2. South Africa
11.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.4.2.2. South Africa Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
11.1.4.2.3. South Africa Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
11.1.4.3. Rest of Middle East & Africa
11.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.4.3.2. Rest of Middle East & Africa Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
11.1.4.3.3. Rest of Middle East & Africa Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
Chapter 12. South America Women’s healthcare Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. South America Women’s healthcare Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.2. South America Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
12.1.3. South America Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
12.1.4. South America Women’s healthcare Market Overview, By Countries, 2015- 2026 (USD Million)
12.1.5. Brazil
12.1.5.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.5.2. Brazil Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
12.1.5.3. Brazil Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
12.1.6. Argentina
12.1.6.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.6.2. Argentina Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
12.1.6.3. Argentina Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
12.1.7. Rest of South America
12.1.7.1. Market Type and projections, 2015 – 2027
12.1.7.2. Rest of South America Women’s healthcare Market Overview, By Type of Drug, 2015 - 2027 (USD Million)
12.1.7.3. Rest of South America Women’s healthcare Market Overview, By application, 2015 - 2027 (USD Million)
Chapter 13. Competitive Landscape
13.1. Competitive environment, 2021
13.2. Strategic framework
13.2.1. Partnership/agreement
13.2.2. Expansion
13.2.3. Mergers & Acquisitions
13.2.4. New Type development
Chapter 14. Key Vendor Analysis
14.1. Bayer AG
14.1.1. Company overview
14.1.2. Financial performance
14.1.3. Product Benchmarking
14.1.4. Recent initiatives
14.1.5. SWOT analysis
14.2. Allergan
14.2.1. Company overview
14.2.2. Financial performance
14.2.3. Product Benchmarking
14.2.4. Recent initiatives
14.2.5. SWOT analysis
14.3. Merck & Co.
14.3.1. Company overview
14.3.2. Financial performance
14.3.3. Product Benchmarking
14.3.4. Recent initiatives
14.4. Pfizer Inc
14.5. Amgen
14.6. Others
Chapter 15. Women’s healthcare Market Cost Analysis
15.1. Women’s healthcare Market Key Type Analysis
15.1.1. Key Type
15.1.2. Price Trend of Key Type
15.1.3. Key Suppliers of Type
15.1.4. Market Concentration Rate of Type
15.1.5. Labor Cost
Chapter 16. Sourcing Strategy and Downstream Buyers
16.1. Women’s healthcare Market Chain Analysis
16.2. Upstream Type Sourcing
16.3. Women’s healthcare Market Major Manufacturers in 2021
16.4. Downstream Buyers
Chapter 17. Marketing Strategy Analysis, Distributors/Traders
17.1. Marketing Channel
17.1.1. Direct Marketing
17.1.2. Indirect Marketing
17.1.3. Marketing Channel Development Trend
17.2. Market Positioning
17.2.1. Pricing Strategy
17.2.2. Brand Strategy
17.2.3. Target Client
17.3. Distributors/Traders List
Chapter 18. Market Effect Factors Analysis
18.1. Technology Progress/Risk
18.1.1. Substitutes Threat
18.1.2. Technology Progress in Related Type
18.2. Consumer Needs/Customer Preference Change
18.3. Economic/Political Environmental Change
Chapter 19. Future Outlook of the Market
Disclaimer 
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Women’s healthcare Market share, By Type of Drug, 2020 & 2027 (%)
10. Global Women’s healthcare Market share, by EVISTA, By Type of Drug, 2015 - 2027 (USD Million)
11. Global Women’s healthcare Market share, by XGEVA, By Type of Drug, 2015 - 2027 (USD Million)
12. Global Women’s healthcare Market share, by Prolia, By Type of Drug, 2015 - 2027 (USD Million)
13. Global Women’s healthcare Market share, by Zometa, By Type of Drug, 2015 - 2027 (USD Million)
14. Global Women’s healthcare Market share, by Reclast, By Type of Drug, 2015 - 2027 (USD Million)
15. Global Women’s healthcare Market share, by Minastrin, By Type of Drug, 2015 - 2027 (USD Million)
16. Global Women’s healthcare Market share, by NuvaRing, By Type of Drug, 2015 - 2027 (USD Million)
17. Global Women’s healthcare Market share, By application, 2020 & 2027 (%)
18. Global Women’s healthcare Market share, by Hormonal infertility, By application, 2015 - 2027 (USD Million)
19. Global Women’s healthcare Market share, by Postmenopausal osteoporosis, By application 2015 - 2027 (USD Million)
20. Global Women’s healthcare Market share, by Endometriosis, By application 2015 - 2027 (USD Million)
21. Global Women’s healthcare Market share, by Contraceptives, By application 2015 - 2027 (USD Million)
22. Global Women’s healthcare Market share, by Menopause, By application 2015 - 2027 (USD Million)
23. Global Women’s healthcare Market share, by region, 2020 & 2027 (%)
24. Global Women’s healthcare Market share, by region, 2015 - 2027(USD Million)
25. North America Women’s healthcare Market, 2015 - 2027(USD Million)
26. North America Women’s healthcare Market share, by Countries, 2020 & 2027 (%)
27. U.S. Women’s healthcare Market, 2015 - 2027(USD Million)
28. Canada Women’s healthcare Market, 2015 - 2027(USD Million)
29. Mexico Women’s healthcare Market, 2015 - 2027(USD Million)
30. Europe Women’s healthcare Market, 2015 - 2027(USD Million)
31. Europe Women’s healthcare Market share, by Countries, 2020 & 2027 (%)
32. Spain Women’s healthcare Market, 2015 - 2027(USD Million)
33. UK Women’s healthcare Market, 2015 - 2027(USD Million)
34. Italy Women’s healthcare Market, 2015 - 2027(USD Million)
35. Germany Women’s healthcare Market, 2015 - 2027(USD Million)
36. France Women’s healthcare Market, 2015 - 2027(USD Million)
37. Rest of Europe Women’s healthcare Market, 2015 - 2027(USD Million)
38. Asia-Pacific Women’s healthcare Market, 2015 - 2027(USD Million)
39. Asia-Pacific Women’s healthcare Market share, by Countries, 2020 & 2027 (%)
40. China Women’s healthcare Market, 2015 - 2027(USD Million)
41. India Women’s healthcare Market, 2015 - 2027(USD Million)
42. Australia Women’s healthcare Market, 2015 - 2027(USD Million)
43. Japan Women’s healthcare Market, 2015 - 2027(USD Million)
44. Rest of Asia-Pacific Women’s healthcare Market, 2015 - 2027(USD Million)
45. Middle East & Africa Women’s healthcare Market, 2015 - 2027(USD Million)
46. Middle East & Africa Women’s healthcare Market share, by Countries, 2020 & 2027 (%)
47. GCC Women’s healthcare Market, 2015 - 2027(USD Million)
48. South Africa Women’s healthcare Market, 2015 - 2027(USD Million)
49. Rest Of Middle East & Africa Women’s healthcare Market, 2015 - 2027(USD Million)
50. South America Women’s healthcare Market, 2015 - 2027(USD Million)
51. Brazil Women’s healthcare Market, 2015 - 2027(USD Million)
52. Mexico Women’s healthcare Market, 2015 - 2027(USD Million)
53. Argentina Women’s healthcare Market, 2015 - 2027(USD Million)
54. Rest of South America Women’s healthcare Market, 2015 - 2027(USD Million)

List of Tables

1. Impact of Market drivers
2. Impact of Market restraints
3. Global Women’s healthcare Market, 2015-2027 (USD Million)
4. Women’s healthcare requirement, by country, 2015-2027, (USD Million)
5. North America Women’s healthcare Market, By Type of Drug, 2015-2027 (USD Million)
6. North America Women’s healthcare Market, By application, 2015-2027 (USD Million)
7. Europe Women’s healthcare Market, By Type of Drug, 2015-2027 (USD Million)
8. Europe Women’s healthcare Market, By application, 2015-2027 (USD Million)
9. Asia Pacific Women’s healthcare Market, By Type of Drug, 2015-2027 (USD Million)
10. Asia Pacific Women’s healthcare Market, By application, 2015-2027 (Revenue, USD Million)
11. Middle East & Africa Women’s healthcare Market, By Type of Drug, 2015-2027 (USD Million)
12. Middle East & Africa Women’s healthcare Market, By application, 2015-2027 (USD Million)
13. South America Women’s healthcare Market, By Type of Drug, 2015-2027 (USD Million)
14. South America Women’s healthcare Market, By application, 2015-2027 (USD Million)
15. Global Women’s healthcare Market, Company Market Share, 2020 - 2027 (%)
16. Bayer AG: Product Benchmarking
17. Bayer AG: Financial Performance
18. Allergan: Product Benchmarking
19. Allergan: Financial Performance
20. Merck & Co..: Product Benchmarking
21. Merck & Co..: Financial Performance
22. Pfizer Inc.: Product Benchmarking
23. Pfizer Inc.: Financial Performance
24. Amgen: Product Benchmarking
25. Amgen: Financial Performance

The Leading Key Players in Womens Healthcare Market

Bayer AG (Germany)
Allergan (Dublin)
Merck & Co. (US)
Pfizer Inc. (US)
Amgen (US)
Agile Therapeutics Inc. (US)
Ferring Pharmaceuticals (US)
Mylan N.V. (US)
Lupin (India)
Blairex Laboratories (US)
Apothecus Pharmaceutical (US).